Dumble Melissa, Gatza Catherine, Tyner Stuart, Venkatachalam Sundaresan, Donehower Lawrence A
Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA.
Ann N Y Acad Sci. 2004 Jun;1019:171-7. doi: 10.1196/annals.1297.027.
Cancer suppression is an integral component of longevity in organisms with renewable tissues. A number of genes in the mammalian genome function in cancer prevention, and some of these have been directly implicated in longevity assurance. One such longevity assurance gene is the tumor suppressor p53, a transcription factor that is mutated or dysregulated in most human cancers. Early studies have linked p53 to the induction of cellular senescence, whereas recent reports implicate it as a potential regulator of organismal aging. We have shown by gene inactivation studies that loss of p53 function enhances tumor susceptibility and reduces longevity in the mouse. A recent serendipitously generated p53 mutant allele resulted in a hypermorphic version of p53 that displays increased cancer resistance, yet also mediates decreased longevity. The reduced longevity is accompanied by the accelerated onset of a variety of aging phenotypes. These include a 20% decrease in median life span, early osteoporosis, lordokyphosis, organ atrophy, delayed wound healing, and a reduced regenerative response after various stresses. Since the initial characterization of these mutant mice, we have attempted to elucidate the underlying molecular and cellular mechanisms that could be influencing the early aging phenotypes. Molecular studies of the p53 mutant allele product indicate that it induces an increase in p53 activity in both in vitro and in vivo contexts. The age-associated loss of organ cellularity and reduced tissue regenerative responses in the mutant mice are consistent with an accelerated loss of stem cell functional capacity. Our model is that enhanced growth inhibitory activity of p53 produces an earlier loss of the ability of stem cells to produce adequate numbers of progenitor and mature differentiated cells in each organ. Currently, we are performing stem cell functional assays from p53 mutant and wild-type mice to test this model. One challenge for the future will be to find ways to manipulate p53 function to provide increased cancer resistance, yet still enhance overall organismal longevity.
癌症抑制是具有可再生组织的生物体长寿的一个不可或缺的组成部分。哺乳动物基因组中的许多基因在癌症预防中发挥作用,其中一些基因与寿命保证直接相关。肿瘤抑制因子p53就是这样一个与寿命保证相关的基因,它是一种转录因子,在大多数人类癌症中发生突变或失调。早期研究将p53与细胞衰老的诱导联系起来,而最近的报道表明它是机体衰老的潜在调节因子。我们通过基因失活研究表明,p53功能的丧失会增强小鼠的肿瘤易感性并缩短其寿命。最近偶然产生的一个p53突变等位基因导致了一个超活性版本的p53,它表现出增强的抗癌能力,但也会缩短寿命。寿命缩短伴随着多种衰老表型的加速出现。这些表型包括中位寿命降低20%、早期骨质疏松、脊柱后凸、器官萎缩、伤口愈合延迟以及各种应激后再生反应减弱。自从最初对这些突变小鼠进行表征以来,我们一直试图阐明可能影响早期衰老表型的潜在分子和细胞机制。对p53突变等位基因产物的分子研究表明,它在体外和体内环境中均会导致p53活性增加。突变小鼠中与年龄相关的器官细胞数量减少和组织再生反应减弱与干细胞功能能力的加速丧失一致。我们的模型是,p53增强的生长抑制活性导致干细胞更早丧失在每个器官中产生足够数量的祖细胞和成熟分化细胞的能力。目前,我们正在对p53突变小鼠和野生型小鼠进行干细胞功能测定以测试该模型。未来的一个挑战将是找到方法来操纵p53功能,以提供增强的抗癌能力,同时仍能提高机体的整体寿命。